-
1
-
-
0027531918
-
Pathogenesis of human immunodeficiency virus infection
-
Levy JA, (1993) Pathogenesis of human immunodeficiency virus infection. MicrobiolRev 57: 183-289.
-
(1993)
MicrobiolRev
, vol.57
, pp. 183-289
-
-
Levy, J.A.1
-
2
-
-
0034723439
-
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
-
Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, et al. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287: 646-650.
-
(2000)
Science
, vol.287
, pp. 646-650
-
-
Hazuda, D.J.1
Felock, P.2
Witmer, M.3
Wolfe, A.4
Stillmock, K.5
-
3
-
-
55049092459
-
HIV type 1 integrase inhibitors: from basic research to clinical implications
-
Jegede O, Babu J, Di Santo R, McColl DJ, Weber J, et al. (2008) HIV type 1 integrase inhibitors: from basic research to clinical implications. AIDS Rev 10: 172-189.
-
(2008)
AIDS Rev
, vol.10
, pp. 172-189
-
-
Jegede, O.1
Babu, J.2
Di Santo, R.3
McColl, D.J.4
Weber, J.5
-
4
-
-
73549123203
-
Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy
-
McColl DJ, Chen X, (2010) Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral research 85: 101-118.
-
(2010)
Antiviral Research
, vol.85
, pp. 101-118
-
-
McColl, D.J.1
Chen, X.2
-
5
-
-
52449097240
-
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection
-
Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, et al. (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. Journal of medicinal chemistry 51: 5843-5855.
-
(2008)
Journal of Medicinal Chemistry
, vol.51
, pp. 5843-5855
-
-
Summa, V.1
Petrocchi, A.2
Bonelli, F.3
Crescenzi, B.4
Donghi, M.5
-
6
-
-
33644863638
-
Novel HIV-1 integrase inhibitors derived from quinolone antibiotics
-
Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, et al. (2006) Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. JMedChem 49: 1506-1508.
-
(2006)
JMedChem
, vol.49
, pp. 1506-1508
-
-
Sato, M.1
Motomura, T.2
Aramaki, H.3
Matsuda, T.4
Yamashita, M.5
-
7
-
-
84878924070
-
Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients
-
Zolopa A, Gallant J, Cohen C, Sax P, Dejesus E, et al. (2012) Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients. Journal of the International AIDS Society 15: 18219.
-
(2012)
Journal of the International AIDS Society
, vol.15
, pp. 18219
-
-
Zolopa, A.1
Gallant, J.2
Cohen, C.3
Sax, P.4
Dejesus, E.5
-
8
-
-
78751697293
-
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor
-
Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, et al. (2011) In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrobial Agents and Chemotherapy 55: 813-821.
-
(2011)
Antimicrobial Agents and Chemotherapy
, vol.55
, pp. 813-821
-
-
Kobayashi, M.1
Yoshinaga, T.2
Seki, T.3
Wakasa-Morimoto, C.4
Brown, K.W.5
-
9
-
-
84874411899
-
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
-
Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, et al. (2013) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet.
-
(2013)
Lancet
-
-
Raffi, F.1
Rachlis, A.2
Stellbrink, H.J.3
Hardy, W.D.4
Torti, C.5
-
11
-
-
79954626457
-
HIV-1 integrase inhibitor resistance and its clinical implications
-
Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW, (2011) HIV-1 integrase inhibitor resistance and its clinical implications. The Journal of infectious diseases 203: 1204-1214.
-
(2011)
The Journal of Infectious Diseases
, vol.203
, pp. 1204-1214
-
-
Blanco, J.L.1
Varghese, V.2
Rhee, S.Y.3
Gatell, J.M.4
Shafer, R.W.5
-
12
-
-
37849002059
-
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)
-
Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, et al. (2008) Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). JVirol 82: 764-774.
-
(2008)
JVirol
, vol.82
, pp. 764-774
-
-
Shimura, K.1
Kodama, E.2
Sakagami, Y.3
Matsuzaki, Y.4
Watanabe, W.5
-
13
-
-
55249105017
-
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors
-
Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, et al. (2008) Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. Journal of Virology 82: 10366-10374.
-
(2008)
Journal of Virology
, vol.82
, pp. 10366-10374
-
-
Goethals, O.1
Clayton, R.2
Van Ginderen, M.3
Vereycken, I.4
Wagemans, E.5
-
14
-
-
84856111536
-
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4
-
Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, et al. (2012) In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral research 93: 288-296.
-
(2012)
Antiviral Research
, vol.93
, pp. 288-296
-
-
Margot, N.A.1
Hluhanich, R.M.2
Jones, G.S.3
Andreatta, K.N.4
Tsiang, M.5
-
15
-
-
40549125135
-
Resistance and cross resistance to fist generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137)
-
McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, et al. (2007) Resistance and cross resistance to fist generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137). Antiviral Therapy 12: S11.
-
(2007)
Antiviral Therapy
, vol.12
-
-
McColl, D.J.1
Fransen, S.2
Gupta, S.3
Parkin, N.4
Margot, N.5
-
16
-
-
77749267991
-
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial
-
Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, et al. (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. JInfectDis 201: 814-822.
-
(2010)
JInfectDis
, vol.201
, pp. 814-822
-
-
Zolopa, A.R.1
Berger, D.S.2
Lampiris, H.3
Zhong, L.4
Chuck, S.L.5
-
17
-
-
78650640149
-
Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates
-
Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, et al. (2011) Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrobial Agents and Chemotherapy 55: 321-325.
-
(2011)
Antimicrobial Agents and Chemotherapy
, vol.55
, pp. 321-325
-
-
van Wesenbeeck, L.1
Rondelez, E.2
Feyaerts, M.3
Verheyen, A.4
van der Borght, K.5
-
18
-
-
84856226017
-
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
-
van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, et al. (2012) Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. The Lancet infectious diseases 12: 111-118.
-
(2012)
The Lancet Infectious Diseases
, vol.12
, pp. 111-118
-
-
van Lunzen, J.1
Maggiolo, F.2
Arribas, J.R.3
Rakhmanova, A.4
Yeni, P.5
-
19
-
-
84863393356
-
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir
-
Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, et al. (2012) Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. Journal of Virology 86: 2696-2705.
-
(2012)
Journal of Virology
, vol.86
, pp. 2696-2705
-
-
Quashie, P.K.1
Mesplede, T.2
Han, Y.S.3
Oliveira, M.4
Singhroy, D.N.5
-
20
-
-
80155188567
-
Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir
-
Canducci F, Ceresola ER, Boeri E, Spagnuolo V, Cossarini F, et al. (2011) Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. The Journal of infectious diseases 204: 1811-1815.
-
(2011)
The Journal of Infectious Diseases
, vol.204
, pp. 1811-1815
-
-
Canducci, F.1
Ceresola, E.R.2
Boeri, E.3
Spagnuolo, V.4
Cossarini, F.5
-
21
-
-
0001769435
-
HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution
-
In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F et al., editors, Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory
-
Quinones-Mateu ME, Arts EJ (2001) HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F et al., editors. HIV Sequence Compendium 2001. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory. 134-170.
-
(2001)
HIV Sequence Compendium 2001
, pp. 134-170
-
-
Quinones-Mateu, M.E.1
Arts, E.J.2
-
22
-
-
0036971250
-
Fitness of drug resistant HIV-1: methodology and clinical implications
-
Quinones-Mateu ME, Arts EJ, (2002) Fitness of drug resistant HIV-1: methodology and clinical implications. Drug ResistUpdat 5: 224-233.
-
(2002)
Drug ResistUpdat
, vol.5
, pp. 224-233
-
-
Quinones-Mateu, M.E.1
Arts, E.J.2
-
23
-
-
30644462096
-
Virus fitness: concept, quantification, and application to HIV population dynamics
-
Quinones-Mateu ME, Arts EJ, (2006) Virus fitness: concept, quantification, and application to HIV population dynamics. Current Topics in Microbiology and Immunology 299: 83-140.
-
(2006)
Current Topics in Microbiology and Immunology
, vol.299
, pp. 83-140
-
-
Quinones-Mateu, M.E.1
Arts, E.J.2
-
24
-
-
0035141001
-
Implications of antiretroviral resistance on viral fitness
-
Nijhuis M, Deeks S, Boucher C, (2001) Implications of antiretroviral resistance on viral fitness. CurrOpinInfectDis 14: 23-28.
-
(2001)
CurrOpinInfectDis
, vol.14
, pp. 23-28
-
-
Nijhuis, M.1
Deeks, S.2
Boucher, C.3
-
25
-
-
84864125870
-
Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo
-
Fransen S, Gupta S, Frantzell A, Petropoulos CJ, Huang W, (2012) Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. Journal of Virology 86: 7249-7255.
-
(2012)
Journal of Virology
, vol.86
, pp. 7249-7255
-
-
Fransen, S.1
Gupta, S.2
Frantzell, A.3
Petropoulos, C.J.4
Huang, W.5
-
26
-
-
70350666377
-
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways
-
Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, et al. (2009) Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. Journal of Virology 83: 11440-11446.
-
(2009)
Journal of Virology
, vol.83
, pp. 11440-11446
-
-
Fransen, S.1
Gupta, S.2
Danovich, R.3
Hazuda, D.4
Miller, M.5
-
27
-
-
62549166235
-
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients
-
Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, et al. (2009) Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. The Journal of antimicrobial chemotherapy 63: 795-804.
-
(2009)
The Journal of Antimicrobial Chemotherapy
, vol.63
, pp. 795-804
-
-
Malet, I.1
Delelis, O.2
Soulie, C.3
Wirden, M.4
Tchertanov, L.5
-
28
-
-
70349272200
-
Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes
-
Quercia R, Dam E, Perez-Bercoff D, Clavel F, (2009) Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. Journal of Virology 83: 10245-10249.
-
(2009)
Journal of Virology
, vol.83
, pp. 10245-10249
-
-
Quercia, R.1
Dam, E.2
Perez-Bercoff, D.3
Clavel, F.4
-
29
-
-
77957310350
-
Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness
-
Hu Z, Kuritzkes DR, (2010) Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. Journal of Acquired Immune Deficiency Syndromes 55: 148-155.
-
(2010)
Journal of Acquired Immune Deficiency Syndromes
, vol.55
, pp. 148-155
-
-
Hu, Z.1
Kuritzkes, D.R.2
-
30
-
-
77956109186
-
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors
-
Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, et al. (2010) Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrobial Agents and Chemotherapy 54: 3938-3948.
-
(2010)
Antimicrobial Agents and Chemotherapy
, vol.54
, pp. 3938-3948
-
-
Ceccherini-Silberstein, F.1
Van Baelen, K.2
Armenia, D.3
Trignetti, M.4
Rondelez, E.5
-
31
-
-
77957862994
-
Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity
-
Fun A, Van Baelen K, van Lelyveld SF, Schipper PJ, Stuyver LJ, et al. (2010) Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity. The Journal of antimicrobial chemotherapy 65: 2300-2304.
-
(2010)
The Journal of Antimicrobial Chemotherapy
, vol.65
, pp. 2300-2304
-
-
Fun, A.1
Van Baelen, K.2
van Lelyveld, S.F.3
Schipper, P.J.4
Stuyver, L.J.5
-
32
-
-
62149093020
-
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation
-
Delelis O, Malet I, Na L, Tchertanov L, Calvez V, et al. (2009) The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Research 37: 1193-1201.
-
(2009)
Nucleic Acids Research
, vol.37
, pp. 1193-1201
-
-
Delelis, O.1
Malet, I.2
Na, L.3
Tchertanov, L.4
Calvez, V.5
-
33
-
-
70349337790
-
Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure
-
Fransen S, Karmochkine M, Huang W, Weiss L, Petropoulos CJ, et al. (2009) Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrobial Agents and Chemotherapy 53: 4522-4524.
-
(2009)
Antimicrobial Agents and Chemotherapy
, vol.53
, pp. 4522-4524
-
-
Fransen, S.1
Karmochkine, M.2
Huang, W.3
Weiss, L.4
Petropoulos, C.J.5
-
34
-
-
70350156722
-
The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy
-
Ferns RB, Kirk S, Bennett J, Cook PM, Williams I, et al. (2009) The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 23: 2159-2164.
-
(2009)
AIDS
, vol.23
, pp. 2159-2164
-
-
Ferns, R.B.1
Kirk, S.2
Bennett, J.3
Cook, P.M.4
Williams, I.5
-
35
-
-
84856247092
-
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing
-
Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, et al. (2012) Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. The Journal of infectious diseases 205: 557-567.
-
(2012)
The Journal of Infectious Diseases
, vol.205
, pp. 557-567
-
-
Armenia, D.1
Vandenbroucke, I.2
Fabeni, L.3
Van Marck, H.4
Cento, V.5
-
36
-
-
84878886967
-
Effect of primary elvitegravir resistance mutations in HIV-1 integrase on drug susceptibility and viral replication fitness
-
Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, et al. (2012) Effect of primary elvitegravir resistance mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antivir Ther 17: A11.
-
(2012)
Antivir Ther
, vol.17
-
-
Abram, M.E.1
Hluhanich, R.M.2
Goodman, D.D.3
Andreatta, K.N.4
Margot, N.A.5
-
37
-
-
52749097450
-
Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: a novel mutation L68V/I associates with E92Q and increase resistance
-
Sitges, Spain
-
Goodman D, Hluhanich R, Waters J, Margot N, Fransen S, et al. (2008) Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: a novel mutation L68V/I associates with E92Q and increase resistance. XVII International HIV Drug Resistance Workshop, Sitges, Spain.
-
(2008)
XVII International HIV Drug Resistance Workshop
-
-
Goodman, D.1
Hluhanich, R.2
Waters, J.3
Margot, N.4
Fransen, S.5
-
38
-
-
84873649469
-
Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness
-
Mesplede T, Quashie P, Oliveira M, Underwood M, Wang R, et al. (2012) Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness. Journal of the International AIDS Society 15: 18113.
-
(2012)
Journal of the International AIDS Society
, vol.15
, pp. 18113
-
-
Mesplede, T.1
Quashie, P.2
Oliveira, M.3
Underwood, M.4
Wang, R.5
-
39
-
-
84874039772
-
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
-
Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, et al. (2013) Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22.
-
(2013)
Retrovirology
, vol.10
, pp. 22
-
-
Mesplede, T.1
Quashie, P.K.2
Osman, N.3
Han, Y.4
Singhroy, D.N.5
-
40
-
-
79959290604
-
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption
-
Canducci F, Barda B, Ceresola E, Spagnuolo V, Sampaolo M, et al. (2011) Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 17: 928-934.
-
(2011)
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
, vol.17
, pp. 928-934
-
-
Canducci, F.1
Barda, B.2
Ceresola, E.3
Spagnuolo, V.4
Sampaolo, M.5
-
41
-
-
69449101785
-
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
-
Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, et al. (2009) Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374: 796-806.
-
(2009)
Lancet
, vol.374
, pp. 796-806
-
-
Lennox, J.L.1
DeJesus, E.2
Lazzarin, A.3
Pollard, R.B.4
Madruga, J.V.5
-
42
-
-
84894019450
-
Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients
-
Rockstroh J, Dejesus E, Henry K, Molina J, Gathe J, et al. (2012) Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients. Journal of the International AIDS Society 15: 18220.
-
(2012)
Journal of the International AIDS Society
, vol.15
, pp. 18220
-
-
Rockstroh, J.1
Dejesus, E.2
Henry, K.3
Molina, J.4
Gathe, J.5
-
43
-
-
47949114939
-
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
-
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, et al. (2008) Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. NEnglJMed 359: 355-365.
-
(2008)
NEnglJMed
, vol.359
, pp. 355-365
-
-
Cooper, D.A.1
Steigbigel, R.T.2
Gatell, J.M.3
Rockstroh, J.K.4
Katlama, C.5
-
44
-
-
63449110982
-
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss
-
Dam E, Quercia R, Glass B, Descamps D, Launay O, et al. (2009) Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoSPathog 5: e1000345.
-
(2009)
PLoSPathog
, vol.5
-
-
Dam, E.1
Quercia, R.2
Glass, B.3
Descamps, D.4
Launay, O.5
-
45
-
-
79953228889
-
Positive Impact of HIV-1 Gag Cleavage Site Mutations on Virological Response to Darunavir Boosted with Ritonavir
-
Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S, Visseaux B, et al. (2011) Positive Impact of HIV-1 Gag Cleavage Site Mutations on Virological Response to Darunavir Boosted with Ritonavir. AntimicrobAgents Chemother.
-
(2011)
AntimicrobAgents Chemother
-
-
Larrouy, L.1
Lambert-Niclot, S.2
Charpentier, C.3
Fourati, S.4
Visseaux, B.5
-
46
-
-
77951213245
-
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance
-
Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, et al. (2010) Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. AntimicrobAgents Chemother 54: 1973-1980.
-
(2010)
AntimicrobAgents Chemother
, vol.54
, pp. 1973-1980
-
-
Gupta, S.1
Fransen, S.2
Paxinos, E.E.3
Stawiski, E.4
Huang, W.5
-
47
-
-
52049107430
-
Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and -independent mechanisms
-
Ehteshami M, Beilhartz GL, Scarth BJ, Tchesnokov EP, McCormick S, et al. (2008) Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and-independent mechanisms. JBiolChem 283: 22222-22232.
-
(2008)
JBiolChem
, vol.283
, pp. 22222-22232
-
-
Ehteshami, M.1
Beilhartz, G.L.2
Scarth, B.J.3
Tchesnokov, E.P.4
McCormick, S.5
-
48
-
-
73649137500
-
The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates
-
Buzon MJ, Dalmau J, Puertas MC, Puig J, Clotet B, et al. (2010) The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 24: 17-25.
-
(2010)
AIDS
, vol.24
, pp. 17-25
-
-
Buzon, M.J.1
Dalmau, J.2
Puertas, M.C.3
Puig, J.4
Clotet, B.5
-
49
-
-
79960330731
-
Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy
-
Weber J, Vazquez AC, Winner D, Rose JD, Wylie D, et al. (2011) Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy. Antimicrobial Agents and Chemotherapy 55: 3729-3742.
-
(2011)
Antimicrobial Agents and Chemotherapy
, vol.55
, pp. 3729-3742
-
-
Weber, J.1
Vazquez, A.C.2
Winner, D.3
Rose, J.D.4
Wylie, D.5
-
50
-
-
79960315643
-
Novel anti-HIV-1 screening system based on intact recombinant viruses expressing synthetic firefly and renilla luminescent proteins
-
Weber J, Quinones-Mateu ME, (2007) Novel anti-HIV-1 screening system based on intact recombinant viruses expressing synthetic firefly and renilla luminescent proteins. AntivirTher 12: S155.
-
(2007)
AntivirTher
, vol.12
-
-
Weber, J.1
Quinones-Mateu, M.E.2
-
51
-
-
33745158157
-
A simple method of estimating fifty percent endpoints
-
Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. AmJHyg 27 493-497.
-
(1938)
AmJHyg
, vol.27
, pp. 493-497
-
-
Reed, L.J.1
Muench, H.2
-
52
-
-
79953049919
-
Human Immunodeficiency Virus Type 1 Resistance or Cross-resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides
-
Selhorst P, Vazquez AC, Terrazas-Aranda K, Michiels J, Vereecken K, et al. (2011) Human Immunodeficiency Virus Type 1 Resistance or Cross-resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides. AntimicrobAgents Chemother 55: 1403-1413.
-
(2011)
AntimicrobAgents Chemother
, vol.55
, pp. 1403-1413
-
-
Selhorst, P.1
Vazquez, A.C.2
Terrazas-Aranda, K.3
Michiels, J.4
Vereecken, K.5
-
53
-
-
0033803642
-
A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression
-
Quinones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, et al. (2000) A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. JVirol 74: 9222-9233.
-
(2000)
JVirol
, vol.74
, pp. 9222-9233
-
-
Quinones-Mateu, M.E.1
Ball, S.C.2
Marozsan, A.J.3
Torre, V.S.4
Albright, J.L.5
-
54
-
-
33745886803
-
Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness
-
Weber J, Weberova J, Carobene M, Mirza M, Martinez-Picado J, et al. (2006) Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods 136: 102-117.
-
(2006)
J Virol Methods
, vol.136
, pp. 102-117
-
-
Weber, J.1
Weberova, J.2
Carobene, M.3
Mirza, M.4
Martinez-Picado, J.5
-
55
-
-
0042405174
-
A Novel TaqMan Real-Time PCR Assay to Estimate ex vivo Human Immunodeficiency Virus type 1 Fitness in the Era of Multi-Target (pol and env) Antiretroviral Therapy
-
Weber J, Rangel HR, Chakraborty B, Tadele M, Martinez MA, et al. (2003) A Novel TaqMan Real-Time PCR Assay to Estimate ex vivo Human Immunodeficiency Virus type 1 Fitness in the Era of Multi-Target (pol and env) Antiretroviral Therapy. Journal of General Virology 84: 2217-2228.
-
(2003)
Journal of General Virology
, vol.84
, pp. 2217-2228
-
-
Weber, J.1
Rangel, H.R.2
Chakraborty, B.3
Tadele, M.4
Martinez, M.A.5
-
56
-
-
67651015445
-
A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates
-
Dudley DM, Gao Y, Nelson KN, Henry KR, Nankya I, et al. (2009) A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques 46: 458-467.
-
(2009)
Biotechniques
, vol.46
, pp. 458-467
-
-
Dudley, D.M.1
Gao, Y.2
Nelson, K.N.3
Henry, K.R.4
Nankya, I.5
-
57
-
-
77953789703
-
Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients
-
Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, et al. (2010) Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naive HIV-infected patients. AntimicrobAgents Chemother 54: 2910-2919.
-
(2010)
AntimicrobAgents Chemother
, vol.54
, pp. 2910-2919
-
-
Larrouy, L.1
Chazallon, C.2
Landman, R.3
Capitant, C.4
Peytavin, G.5
-
58
-
-
38049028352
-
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance
-
Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, et al. (2007) N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoSMed 4: e335.
-
(2007)
PLoSMed
, vol.4
-
-
Yap, S.H.1
Sheen, C.W.2
Fahey, J.3
Zanin, M.4
Tyssen, D.5
-
59
-
-
59649106106
-
Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility
-
Ehteshami M, Gotte M, (2008) Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. AIDS Rev 10: 224-235.
-
(2008)
AIDS Rev
, vol.10
, pp. 224-235
-
-
Ehteshami, M.1
Gotte, M.2
-
60
-
-
65549142692
-
Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase
-
Wilkinson TA, Januszyk K, Phillips ML, Tekeste SS, Zhang M, et al. (2009) Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. JBiolChem 284: 7931-7939.
-
(2009)
JBiolChem
, vol.284
, pp. 7931-7939
-
-
Wilkinson, T.A.1
Januszyk, K.2
Phillips, M.L.3
Tekeste, S.S.4
Zhang, M.5
-
61
-
-
77957875432
-
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors
-
Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, et al. (2010) Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. The Journal of antimicrobial chemotherapy 65: 2305-2318.
-
(2010)
The Journal of Antimicrobial Chemotherapy
, vol.65
, pp. 2305-2318
-
-
Ceccherini-Silberstein, F.1
Malet, I.2
Fabeni, L.3
Dimonte, S.4
Svicher, V.5
-
62
-
-
84864007971
-
Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations
-
Winters MA, Lloyd RM Jr, Shafer RW, Kozal MJ, Miller MD, et al. (2012) Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PloS one 7: e40514.
-
(2012)
PloS One
, vol.7
-
-
Winters, M.A.1
Lloyd Jr., R.M.2
Shafer, R.W.3
Kozal, M.J.4
Miller, M.D.5
-
63
-
-
9444282038
-
Evidence for positive epistasis in HIV-1
-
Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ, (2004) Evidence for positive epistasis in HIV-1. Science 306: 1547-1550.
-
(2004)
Science
, vol.306
, pp. 1547-1550
-
-
Bonhoeffer, S.1
Chappey, C.2
Parkin, N.T.3
Whitcomb, J.M.4
Petropoulos, C.J.5
-
64
-
-
79955423458
-
A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase
-
Hinkley T, Martins J, Chappey C, Haddad M, Stawiski E, et al. (2011) A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nature genetics 43: 487-489.
-
(2011)
Nature Genetics
, vol.43
, pp. 487-489
-
-
Hinkley, T.1
Martins, J.2
Chappey, C.3
Haddad, M.4
Stawiski, E.5
-
66
-
-
77956641491
-
Fitness Epistasis and Constraints on Adaptation in a Human Immunodeficiency Virus Type 1 Protein Region
-
da SJ, Coetzer M, Nedellec R, Pastore C, Mosier DE (2010) Fitness Epistasis and Constraints on Adaptation in a Human Immunodeficiency Virus Type 1 Protein Region. Genetics.
-
(2010)
Genetics
-
-
da, S.J.1
Coetzer, M.2
Nedellec, R.3
Pastore, C.4
Mosier, D.E.5
-
67
-
-
68949209095
-
Epistasis among deleterious mutations in the HIV-1 protease
-
Parera M, Perez-Alvarez N, Clotet B, Martinez MA, (2009) Epistasis among deleterious mutations in the HIV-1 protease. Journal of Molecular Biology 392: 243-250.
-
(2009)
Journal of Molecular Biology
, vol.392
, pp. 243-250
-
-
Parera, M.1
Perez-Alvarez, N.2
Clotet, B.3
Martinez, M.A.4
-
68
-
-
79953669224
-
Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1
-
Martinez JP, Bocharov G, Ignatovich A, Reiter J, Dittmar MT, et al. (2011) Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1. PloS one 6: e18375.
-
(2011)
PloS One
, vol.6
-
-
Martinez, J.P.1
Bocharov, G.2
Ignatovich, A.3
Reiter, J.4
Dittmar, M.T.5
-
69
-
-
0042816457
-
Role of baseline pol genotype in HIV-1 fitness evolution
-
Weber J, Rangel HR, Chakraborty B, Marotta ML, Valdez H, et al. (2003) Role of baseline pol genotype in HIV-1 fitness evolution. JAIDS 33: 448-460.
-
(2003)
JAIDS
, vol.33
, pp. 448-460
-
-
Weber, J.1
Rangel, H.R.2
Chakraborty, B.3
Marotta, M.L.4
Valdez, H.5
|